Testing a new weight-loss drug for people who couldn't tolerate GLP-1 shots
Treatments studied
Part of Hormones & metabolism clinical trials.
This study tests a new injectable medication called cagrilintide for people with obesity who had to stop GLP-1 drugs (like Ozempic or Wegovy) because of stomach problems. The goal is to see if cagrilintide causes fewer stomach side effects while still helping with weight.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You tried a GLP-1 medication but stopped it mainly because of stomach or digestive problems (nausea, vomiting, constipation, etc.)
- Your doctor believes you should not restart GLP-1 drugs
- Your BMI is 30 or higher (generally considered obese)
- You have not taken any GLP-1 medication or other weight-loss drugs in the past 8 weeks
- You do not have type 1 or type 2 diabetes and your blood sugar is normal
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two different versions of an investigational weight-loss medication (cagrilintide) against a placebo to see which is more effective and safe for people with excess weight. Participation involves receiving injections and regular check-ins to monitor your progress.
This early-stage study tests a new medication called cagrilintide to see how it influences appetite and food intake in adults with overweight or obesity. Researchers want to understand if this drug could help people feel fuller and eat less.
This early-stage study tests different formulations of cagrilintide, a new medication, to see how the body absorbs and processes each version. Cagrilintide may help with weight management. Researchers will measure blood levels after you receive multiple doses.
This trial tests whether cagrilintide, a medicine similar to a natural hormone called amylin, can affect bone health. It is for postmenopausal women with obesity who do not have bone disease or other conditions affecting bone metabolism.
This study tests how two medicines, cagrilintide and semaglutide, affect your metabolism compared to diet alone. It may help you understand how weight loss changes your body's energy use.
This study tests a new medication called CagriSema to understand how it affects muscle health while helping people lose weight. You'll be in the trial for about a year, and researchers will monitor your muscle function and body composition.
Hear when a new Obesity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.